. 2021 Apr;12(Suppl 1):S144–S181. doi: 10.21037/jgo-2020-06

Table 8. Prospective observational studies focus on intraperitoneal chemotherapy for primary and recurrent EOC.

First authors (ref.)	Year	Case-control or cohort	Primitive/Recurrence	FIGO (Inclusion of persistent EOC^§?)	IP therapy technique	no. of pts	Chemotherapy regimen	Platinum-Sensitive pts	CC0-1 n (%)	OS (months) [5y-OS%]		DFS or PFS° (months)		Morbidity (3-4 grade/severe) %	Mortality %
Ansaloni (94)	2012	Cohort	pEOC	IIIC	HIPEC	9	CRS+HIPEC with Cis 100 mg/m² and/or Paclitaxel 175 mg/m² and/or Doxo 35 mg/m²	Platinum-S: 33%, Platinum-R: 62%	CC-0: 35 (90), CC-1: 3 (7), CC-3: 1 (3)	–		Mean DFS: 14.4		(18)	2.5
Ansaloni (94)	2012	Cohort	rEOC	IIIC	HIPEC	30		Platinum-S: 33%, Platinum-R: 62%	CC-0: 35 (90), CC-1: 3 (7), CC-3: 1 (3)	–		Mean DFS: 14.4		(18)	2.5
Ansaloni (95)	2015	Cohort	pEOC	IIIC-IV	HIPEC	9	CRS+HIPEC with Cis 100 mg/m² and Paclitaxel 175 mg/m²	Platinum-S: 100%	CC-0: 13 (100)	–		–		100 (61.5)	0
Ansaloni (95)	2015	Cohort	rEOC	IIIC-IV	HIPEC	4	CRS+HIPEC with Cis 100 mg/m² and Paclitaxel 175 mg/m²	Platinum-S: 100%	CC-0: 13 (100)	–		–		100 (61.5)	0
Coccolini (96)	2015	Cohort	pEOC	IIIC-IV	HIPEC	30	(ev. NACT) + CRS+HIPEC with Cis 100 mg/m² + Paclitaxel 175 mg/m²	Platinum-S: 68.5%, Platinum-R: 31.49%	CC-0: 47 (87), CC-1: 7 (13)	32.9	22	12.5	13	95.2 (35.2)	5.6
Coccolini (96)	2015	Cohort	rEOC	IIIC-IV	HIPEC	24		Platinum-S: 68.5%, Platinum-R: 31.49%	CC-0: 47 (87), CC-1: 7 (13)	32.9	44	12.5	12	95.2 (35.2)	5.6
Di Giorgio (79)	2008	Cohort	pEOC	IIIC-IV	HIPEC	22	CRS+HIPEC with Cis 75 mg/m²	–	CC-0,1: 41 (87.2), CC-2,3: 6 (12.8)	27	PCI <15: 24; PCI >15: 26; CC-0: 26; CC-1: 13; CC-2,3: 12	25.5	PCI <15: 21; PCI >15: 20; CC-0: 24; CC-1: 13; CC-2,3: 6	48.9 (21.3)	4.2
Di Giorgio (79)	2008	Cohort	rEOC	IIIC-IV	HIPEC	25	CRS+HIPEC with Cis 75 mg/m²	–	CC-0,1: 41 (87.2), CC-2,3: 6 (12.8)	22.5	PCI <15: 24; PCI >15: 26; CC-0: 26; CC-1: 13; CC-2,3: 12	15.5	PCI <15: 21; PCI >15: 20; CC-0: 24; CC-1: 13; CC-2,3: 6	48.9 (21.3)	4.2
Gonzalez Bayon (97)	2013	Cohort	pEOC	IIIC-IV	HIPEC + EPIC	15	NACT + CRS + HIPEC with Cis 100 mg/m² + Doxo 30 mg/m² + ev. EPIC with Taxol 20 mg/m² for 5 days	–	CC-0: 11 (73.3)	77.8		21.1 (72)		26.6	6.6
			rEOC			19 first recurrence, 8 second recurrence			First recur. CC-0: 14 (73.6)	First recur. 62.8		First recur. 18.1 (62.2)		21	5.2
			rEOC			19 first recurrence, 8 second recurrence			Second or subsequent recurrence CC-0: 6 (75)	Second or subsequent recurrence: 35.7		Second or subsequent recurrence: 5.7 (17.9)		37.5	12.5
Pomel (98)	2010	Cohort	cEOC+rEOC	IIIC (yes)	HIPEC	31	CRS + post-op IV CT with Cis 6 cycles + second-look laparotomy + HIPEC with Oxa 460 mg/m²	–	CC-0 31 (100)	[2y-OS 67%]		[2y-DFS 27%]		(29)	0
Tentes (99)	2012	Cohort	pEOC	–	HIPEC	23	CRS+HIPEC with Cis 50 mg/m² + Doxo 15 mg/m² or Gem 1000 mg/m² in Platinum-R	–	CC-0: 30 (69.8)	37		–		(14)	4.7
Tentes (99)	2012	Cohort	rEOC	–	HIPEC	20		–	CC-0: 30 (69.8)	37		–		(14)	4.7

^§EOC with sub-optimal cytoreduction at primary surgery and evidence of persistent peritoneal disease; Cis, Cisplatin; Doxo, Doxorubicin; MMC, Mitomycin C; Oxa, Oxaliplatin; Carbo, Carboplatin; Gem, Gemcitabine; CT, chemotherapy; Ca-Co, case-control; rEOC, recurrent EOC; pEOC, primary EOC; cEOC, HIPEC for consolidation; NA, not available.